Insider Buying: Lyell Immunopharma, Inc. (NASDAQ:LYEL) Director Purchases 35,640 Shares of Stock

Lyell Immunopharma, Inc. (NASDAQ:LYEL) Director Otis W. Brawley bought 35,640 shares of the business’s stock in a transaction that occurred on Monday, March 31st. The stock was purchased at an average price of $0.56 per share, with a total value of $19,958.40. Following the completion of the purchase, the director now directly owns 35,640 shares of the company’s stock, valued at $19,958.40. This represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Lyell Immunopharma Stock Up 4.8 %

LYEL traded up $0.02 during midday trading on Wednesday, reaching $0.51. 453,376 shares of the company’s stock were exchanged, compared to its average volume of 1,055,784. The business has a 50-day simple moving average of $0.61 and a two-hundred day simple moving average of $0.85. The firm has a market capitalization of $149.83 million, a price-to-earnings ratio of -0.64 and a beta of -0.41. Lyell Immunopharma, Inc. has a one year low of $0.48 and a one year high of $3.15.

Lyell Immunopharma (NASDAQ:LYEL) last announced its quarterly earnings results on Wednesday, March 12th. The company reported ($0.72) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.52). Lyell Immunopharma had a negative net margin of 323,792.09% and a negative return on equity of 34.64%. The company had revenue of $0.01 million during the quarter. As a group, research analysts anticipate that Lyell Immunopharma, Inc. will post -0.78 EPS for the current fiscal year.

Institutional Investors Weigh In On Lyell Immunopharma

Several institutional investors and hedge funds have recently made changes to their positions in LYEL. Centiva Capital LP bought a new position in Lyell Immunopharma during the 3rd quarter valued at about $31,000. Intech Investment Management LLC acquired a new stake in shares of Lyell Immunopharma during the third quarter worth approximately $52,000. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Lyell Immunopharma in the third quarter valued at approximately $52,000. Graham Capital Management L.P. acquired a new position in shares of Lyell Immunopharma in the 4th quarter worth approximately $33,000. Finally, Erste Asset Management GmbH bought a new stake in Lyell Immunopharma during the 3rd quarter worth approximately $82,000. Institutional investors and hedge funds own 66.05% of the company’s stock.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “neutral” rating and issued a $1.00 price target on shares of Lyell Immunopharma in a report on Thursday, March 13th.

About Lyell Immunopharma

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.